Ivrea, Italy – 16th June, 2008 – Creabilis Therapeutics SpA, an emerging specialty pharmaceutical company focused on dermatology, today announced the appointment of Tony Wilson as Chief Executive Officer with immediate effect. Mr Wilson brings to Creabilis a broad knowledge of the biotechnology and pharmaceutical industry combined with first hand experience of the dermatology sector.
He has over 25 years industry experience gained for the most part at Leo Pharmaceuticals a company engaged in clinical research, manufacture, marketing and sales of Leo Group products in the UK. While at Leo Pharmaceuticals Mr Wilson has been involved in the development and marketing of Dovonex and Dovobet, two of the most successful products in the history of dermatology.
Commenting on his new role, Mr Wilson said:
“Creabilis is at an exciting stage of development and I look forward to contributing to the future growth of the Company. I am convinced that Creabilis is in an excellent position to become a successful dermatology business as it has a rich pipeline of clinical and pre-clinical drug candidates focussed on dermatological indications, a deep understanding of the science behind a number of serious skin disorders, and a driven management team backed by experienced international investors and board members.”
Mr Wilson joins Creabilis from Janus Pharmaceuticals, Inc. a US-headquartered dermatology company with its lead product, luliconazole, a novel topical prescription anti-fungal product, in late stage development in the USA and Europe. Prior to that he was co-founder and CEO of Salveo Pharmaceuticals Ltd. Salveo was a speciality pharmaceutical company whose objectives were to acquire and market dermatology products in Europe.
Claudio Nessi, Partner at NeoMed, said: “We are delighted to have such an experienced industry professional managing Creabilis. Tony brings with him significant understanding of the dermatology market, hands-on experience of developing and commercialising high value brands and has proven abilities in raising funds to allow companies to grow. We are certain Tony will contribute greatly to Creabilis achieving its goal of becoming a specialty pharma company marketing their own new prescription medicines to treat skin diseases in niche indications and through licensing in larger indications.”
For further information please contact:
Tony Wilson /Silvio Traversa
Tel: +39 0125 53543
Citigate Dewe Rogerson
Chris Gardner or Sylvie Berrebi
Tel: +44 (0)20 7282 1050
About Creabilis Therapeutics SpA
Creabilis Therapeutics is an Italian specialty pharmaceutical company discovering, developing and commercializing new products to treat skin disorders, an area of significant unmet medical need and high commercial potential. Founded in 2003, Creabilis is located in the Bioindustry Park del Canavese Ivrea, Italy. Creabilis’ strategy is to commercialize its products directly through its own marketing efforts in niche indications or through co marketing or licensing with partners in larger indications. The Company has a rich pipeline of clinical and pre-clinical drug candidates focussed on dermatological indications. Its most advanced products are: CT327 for the treatment of psoriasis, dermatitis and other skin conditions characterised by the hyperproliferation of keratinocytes; and CT200 which is being developed for the treatment of Behcet’s Disease. Both products are entering Phase II clinical trials in 2008. In addition, Creabilis has a number of drug candidates in the later pre-clinical stages of development.
For more information, please visit: www.creabilistherapeutics.com